RA
BPMC

Rise Advisors’s Blueprint Medicines BPMC Stock Holding History

Rise Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-134
Closed -$17.2K – 1536
2025
Q2 		$17.2K Hold
134
– – 0.01% 627
2025
Q1 		$11.9K Sell
134
-22
-14% -$2.15K 0.01% 854
2024
Q4 		$13.6K Hold
156
– – 0.01% 875
2024
Q3 		$14.4K Hold
156
– – 0.01% 880
2024
Q2 		$16.8K Hold
156
– – 0.01% 750
2024
Q1 		$14.8K Buy
+156
New +$13.4K 0.01% 865

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Rise Advisors's BPMC Position: Q3 2025 in Review

Rise Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 134 shares — an estimated $17.2K sold.

Rise Advisors first reported a position in BPMC in Q1 2024 and held it in 6 quarters. The position peaked at $17.2K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Rise Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Rise Advisors sold 134 Blueprint Medicines shares in Q3 2025, an estimated $17.2K.
  • Rise Advisors first reported a position in Blueprint Medicines in Q1 2024 and held it in 6 quarters.
  • Rise Advisors's Blueprint Medicines position peaked at $17.2K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Rise Advisors's 13F filing for Q3 2025, filed 8 Oct 2025.